| Nov 15 |
These 2 “Strong Buy” Penny Stocks Are Set to Triple (or more), Say Analysts
|
| Nov 9 |
SAB Biotherapeutics Third Quarter 2024 Earnings: US$1.12 loss per share (vs US$0.97 loss in 3Q 2023)
|
| Nov 7 |
SAB Biotherapeutics GAAP EPS of -$1.12
|
| Nov 6 |
SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update
|
| Oct 31 |
SAB BIO CEO to Participate in Fireside Chat at Guggenheim Securities Healthcare Innovation Conference
|
| Sep 23 |
SAB Biotherapeutics (NASDAQ:SABS) Will Have To Spend Its Cash Wisely
|
| Sep 13 |
SAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare Conference
|
| Sep 9 |
SAB BIO Provides SAB-142 Clinical Trial Progress Update at the European Association for the Study of Diabetes Annual Meeting
|
| Sep 4 |
SAB BIO to Present at the European Association for the Study of Diabetes 60th Annual Meeting
|
| Aug 9 |
SAB Biotherapeutics GAAP EPS of -$0.79
|
